• Je něco špatně v tomto záznamu ?

Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial

V. Melenovský, E. Hošková, K. Velebová, J. Veleba, BA. Borlaug, J. Benes, O. Kuda, T. Čajka, M. Segeťová, L. Thieme, J. Kopecký, J. Kopecký, T. Pelikánová, M. Haluzík, M. Hill, H. Kahleová

. 2025 ; 43 (1) : 23-32. [pub] 20240909

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25008741

This randomized trial tested the effect of metformin on glycemic control and cardiac function in patients with heart failure (HF) and type 2 diabetes while evaluating intestinal effects on selected gut microbiome products reflected by trimethylamine-N-oxide (TMAO) and gut-derived incretins. Metformin treatment improved glycemic control and postprandial metabolism and enhanced postprandial glucagon-like peptide 1 (GLP-1) secretion but did not influence cardiac function or the TMAO levels. Metabolic effects of metformin in HF may be mediated by an improvement in intestinal endocrine function and enhanced secretion of the gut-derived incretin GLP-1.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008741
003      
CZ-PrNML
005      
20250422095616.0
007      
ta
008      
250408s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.2337/cd24-0003 $2 doi
035    __
$a (PubMed)39829685
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Melenovský, Vojtěch $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
245    10
$a Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial / $c V. Melenovský, E. Hošková, K. Velebová, J. Veleba, BA. Borlaug, J. Benes, O. Kuda, T. Čajka, M. Segeťová, L. Thieme, J. Kopecký, J. Kopecký, T. Pelikánová, M. Haluzík, M. Hill, H. Kahleová
520    9_
$a This randomized trial tested the effect of metformin on glycemic control and cardiac function in patients with heart failure (HF) and type 2 diabetes while evaluating intestinal effects on selected gut microbiome products reflected by trimethylamine-N-oxide (TMAO) and gut-derived incretins. Metformin treatment improved glycemic control and postprandial metabolism and enhanced postprandial glucagon-like peptide 1 (GLP-1) secretion but did not influence cardiac function or the TMAO levels. Metabolic effects of metformin in HF may be mediated by an improvement in intestinal endocrine function and enhanced secretion of the gut-derived incretin GLP-1.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hošková, Eva $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Velebová, Kateřina $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Veleba, Jiří $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Borlaug, Barry A $u Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN
700    1_
$a Benes, Jan $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kuda, Ondřej $u Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Čajka, Tomáš $u Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Segeťová, Markéta $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Thieme, Lenka $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kopecký, Jan $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kopecký, Jan $u Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Pelikánová, Terezie $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Haluzík, Martin $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Hill, Martin $u Institute of Endocrinology, Prague, Czech Republic
700    1_
$a Kahleová, Hana $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Physicians Committee for Responsible Medicine, Washington, DC $1 https://orcid.org/0000000304913993 $7 xx0158494
773    0_
$w MED00005854 $t Clinical diabetes $x 0891-8929 $g Roč. 43, č. 1 (2025), s. 23-32
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39829685 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250408 $b ABA008
991    __
$a 20250422095618 $b ABA008
999    __
$a ok $b bmc $g 2306468 $s 1245816
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 43 $c 1 $d 23-32 $e 20240909 $i 0891-8929 $m Clinical diabetes $n Clin Diabetes $x MED00005854
LZP    __
$a Pubmed-20250408

Najít záznam

Citační ukazatele

Možnosti archivace